Abstract
Intense interest in serotonin (5-hydroxytryptamine, 5-HT) stems from the involvement of this biogenic amine in an extraordinary range of physiological functions. (See, for example, the five-volume series edited by Essman, 1977–1979.) Most tissues and organs are affected by 5-HT, either through serotonergic neurons or following its release from blood platelets and other non-neuronal sites. Both platelets and serotonergic neurons have mechanisms for the active uptake of 5-HT, and the platelet has become a model for studying aspects of the regulation of 5-HT levels. The discovery that platelets of endogenously depressed patients have a decreased number of high-affinity binding sites for [3H]-imipramine (Briley et al., 1980; Paul et al., 1981) has kindled research on the imipramine binding site, and this site is now thought to effect a modulation of 5-HT uptake (Wennogle and Meyerson, 1983, 1985; Meyerson et al., submitted).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Abraham, K. I., Ieni, J. R. and Meyerson, L. R., Biochim. Biophys. Acta., submitted.
Abraham, K. I. and Meyerson, L. R., Isolation of a plasma acid protein modulator for the human platelet imipramine binding site, Society for Neuroscience Abstracts 11: 749 (1985).
Badawi, K., Wallace, R. K., Orme-Johnson, D. and Rouzere, A. M., Electrophysiologic characteristics of respiratory suspension periods occuring during the practice of the Transcendental Meditation program, Psychosomatic Medicine 46: 267 (1984).
Barbaccia, M. L., Gandolfi, O., Chuang, D. M. and Costa, E., Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites, Proc. Natl. Acad. Sci. USA 80: 5134 (1983).
Bloom, F. E., Open Questions: a summary of the workshop discussions, in: “Beta-Carbolines and Tetrahydroisoquinolines” (Progress in Clinical and Biological Research; v. 90), P. Bloom, J. Barchas, M. Sandler and Usdin, E., eds., Alan R. Liss, New York (1982).
Briley, M., Imipramine binding: its relationship with serotonin uptake and depression, in: “Neuropharmacology of Serotonin”, A. R., Green, ed., Oxford University Press, New York (1985).
Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D. and Zarifian, E., Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients, Science, 209: 303 (1980).
Bujatti, M. and Riederer, P., Serotonin, noradrenaline and dopamine metabolites in the Transcendental Meditation technique, J. Neural Transm., 39: 257 (1976).
de Montigny, C. and Blier, P., Electrophysiological aspects of serotonin neuropharmacology: implications for antidepressant treatments, in: “Neuropharmacology of Serotonin”, A. R. Green, ed., Oxford University Press, New York (1985).
Clow, A., Glover, V., Armando, I. and Sandler, M., New endogenous benzodiazepine receptor ligand in human urine: identity with endogenous monoamine oxidase inhibitor? Life Sciences, 33: 735 (1983).
Dillbeck, M. C., Orme-Johnson, D. W. and Wallace, R. K., Frontal EEG coherence, H-reflex recovery, concept learning, and the TM-Sidhi program, Internat. J. Neurosci., 15: 151 (1981).
Essman, W. B. (Editor), “Serotonin in Health and Disease”, Vols I-V, Spectrum Publications, Inc., New York (1977–1979).
Farrow, J. T. and Hebert, J. R., Breath suspension during the transcendental meditation technique, Psychosomatic Medicine 44: 131 (1982).
Graeff, F. G., Zuardi, A. W., Giglio, J. S., Lima Filho, E. C. and Karniol, I. G., Effect of metergoline on human anxiety, Psychopharmacology 86: 334 (1985).
Jevning, R., Wilson, A. F. and Davidson, J. M., Adrenocortical activity during meditation, Hormones and Behavior, 10: 54 (1978a).
Jevning, R., Wilson, A. F. and Van der Laan, E. F., Plasma prolactin and growth hormone during meditation, Psychosom. Med. 40: 329 (1978b).
Kesterson, J. and Clinch, N., Peripheral and central control mechanisms during respiratory suspensions in Transcendental Meditation as evidenced by latency, hypoxia and RQ change, Soc. Neurosci. Abstr. 11: 1144 (1985).
Knight, J. A., Robertson, G. and Wu, J. T., The chemical basis and specificity of the nitrosonaphthol reaction, Clin. Chem., 29: 1969 (1983).
Krieger, D. T., Endocrine processes and serotonin, in: “Serotonin in Health and Disease Vol III: The Central Nervous System,” W. B. Essman, ed., Spectrum Publications, Inc., New York (1978).
Lal, H., Laballa, F. and Lane, J., eds., “Endocoids” (Progress in Clinical and Biological Research, v. 192), Alan R. Liss, New York (1985).
Langer, S. Z., Raisman, R., Tahraoui, L., Scatton, B., Niddam, R., Lee, C. R. and Claustre, Y., Substituted tetrahydro-beta-carbolines are possible candidates as endogenous ligand of the 3H-imipramine recognition site, Eur. J. Pharmacol., 98: 153 (1984).
Lundberg, D. B. A., Mueller, R. A. and Breese, G. R., An evaluation of the mechanism by which serotonergic activation depresses respiration, J. Pharmacol. and Exp. Ther. 212: 397 (1980).
Meyerson, L. R., Ieni, J. R. and Wennogle, L. P., Allosteric interactions between platelet imipramine binding and serotonin transport, J. Neurochem (submitted).
Mills, W. W. and Farrow, J. T., The Transcendental Meditation technique and acute experimental pain, Psychosomatic Medicine 43: 157 (1981).
Mustala, O., Specificity of the nitrosonaphthol reaction in the determination of urinary 5-hydroxyindoleacetic acid, Ann. Med. Exp. et Biologie Fenn., 63, Suppl. 8: 1 (1965).
Orme-Johnson, D. W., Autonomie stability and Transcendental Meditation, Psychosomatic Medicine 35: 341 (1973).
Paul, S. M., Rehavi, M., Skolnick, P., Ballenger, J. C. and Goodwin, F. K., Depressed patients have decreased binding of 3H-imipramine to the platelet serotonin “transporter”, Arch. Gen. Psychiat., 38: 1315 (1981).
Rehavi, M., Skolnick, P. and Paul, S. M., High-affinity binding sites for tricyclic antidepressants in brain and platelets in: “Brain Receptor Methodologies. Part B. Amino Acids, Peptides, Psychoactive Drugs,” P. J. Marangos et al., eds., Academic Press, Inc., New York (1984).
Rommelspacher, H., Honecker, H., Barbey, M. and Meinke, B., 6-Hydroxy-tetrahydronorharmane (6-hydroxy-tetrahydro-beta-carboline), a new active metabolite of indole-alkylamines in man and rat, Naunyn-Schmiedeberg’s Arch, Pharmacol., 310: 35 (1979a).
Rommelspacher, H., Strauss, S. and Lindemann, J., Excretion of tetrahydroharmane and harmane into the urine of man and rat after a load with ethanol, EEBS Letters, 109: 209 (1979b).
Sette, M., Briley, M. S. and Langer, S. Z., Complex inhibition of 3H-imipramine binding by serotonin and nontricyclic serotonin uptake blockers, J. Neurochem., 40: 622 (1983).
Shihabi, Z. K. and Wilson, E. L., Colorimetrie assay of urinary 5-hydroxy-3-indoleacetic acid, Clin. Biochem., 15: 106 (1982).
Udenfriend, S., Titus, E. and Weissbach, H., The identification of 5-Hydroxy-3-indoleacetic acid in normal urine and a method for its assay, J. Biol. Chem., 216: 499 (1955).
Walton, K. G., Francis, D., Lerom, M. and Tourenne, C., Behaviorally-induced alterations in urinary 5-hydroxyindoles, Trans. of the Amer. Soc. Neurochem., 14: 199 (1983).
Wennogle, L. P. and Meyerson, L. R., Serotonin modulates the dissociation of 3H-imipramine from human platelet recognition sites, Eur. J. Pharmacol. 86: 303 (1983).
Wennogle, L. P. and Meyerson, L. M., Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelets, Life Sciences 36: 1541 (1985).
Yuwiler, A., Stress and serotonin, in: “Serotonin in Health and Disease Vol. V: Clinical Applications,” W. B. Essman, ed., SP Med and Scientific Books, New York (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Walton, K.G. et al. (1987). “Substance M”, A Serotonin Modulator Candidate from Human Urine?. In: Ehrlich, Y.H., Lenox, R.H., Kornecki, E., Berry, W.O. (eds) Molecular Mechanisms of Neuronal Responsiveness. Advances in Experimental Medicine and Biology, vol 221. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-7618-7_36
Download citation
DOI: https://doi.org/10.1007/978-1-4684-7618-7_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-7620-0
Online ISBN: 978-1-4684-7618-7
eBook Packages: Springer Book Archive